Science News
from research organizations

Cancer research breakthrough: Immune markers discovered that can predict ovarian cancer patients' response to treatment

Date:
March 24, 2015
Source:
Queen's University
Summary:
A biomarker that will help lead to better predictions of the success of chemotherapy in ovarian cancer patients has been discovered by researchers. This discovery could lead to better treatment options in the fight against ovarian cancer, they say.
Share:
FULL STORY

Queen's University cancer researcher Madhuri Koti has discovered a biomarker that will help lead to better predictions of the success of chemotherapy in ovarian cancer patients. This discovery could lead to better treatment options in the fight against ovarian cancer.

Biomarkers are an indicator of a biological state or condition.

"Recent successes in harnessing the immune system to combat cancer are evidence for the significant roles of a cancer patient's immune responses in fighting cancer," explains Dr. Koti (Biomedical and Molecular Sciences). "Many of these success are based on boosting anti-cancer immunity via different therapies. Such therapies would prove to be most effective when coupled with markers predicting a patient's eventual response to a specific therapy."

Dr. Koti conducted the study in retrospective cohorts of over 200 ovarian cancer patients.

The study utilized a combination of recent cutting-edge and more established detection technologies for identifying such markers. Initial discovery of these markers was made in frozen tumor tissues accrued from tumor banks such as the Ontario Tumor Bank and the Ottawa Health Research Institute and Gynecology-Oncology and Pathology services of the CHUMHospital Notre-Dame, Montreal.

Phase II validations are currently under way in retrospective cohorts of over 500 ovarian cancer patient tumors accrued from the Terry Fox Research Institute-Ovarian Cancer Canada partnered, Canadian Ovarian Experimental Unified Resource.

A major impact of this discovery is that these novel markers, when used at the time of treatment initiation in the specific type of ovarian cancer patient, will help gynecologic oncologists make decisions on additional treatment needed in these patients, thus increasing the potential for patient survival.

Ovarian cancer leads to approximately 152,000 deaths among women worldwide each year, making it a leading cause of gynecological cancer related deaths in women.


Story Source:

Materials provided by Queen's University. Original written by Anne Craig. Note: Content may be edited for style and length.


Journal Reference:

  1. M Koti, A Siu, I Clément, M Bidarimath, G Turashvili, A Edwards, K Rahimi, A-M M Masson, J A Squire. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. British Journal of Cancer, 2015; DOI: 10.1038/bjc.2015.81

Cite This Page:

Queen's University. "Cancer research breakthrough: Immune markers discovered that can predict ovarian cancer patients' response to treatment." ScienceDaily. ScienceDaily, 24 March 2015. <www.sciencedaily.com/releases/2015/03/150324132230.htm>.
Queen's University. (2015, March 24). Cancer research breakthrough: Immune markers discovered that can predict ovarian cancer patients' response to treatment. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2015/03/150324132230.htm
Queen's University. "Cancer research breakthrough: Immune markers discovered that can predict ovarian cancer patients' response to treatment." ScienceDaily. www.sciencedaily.com/releases/2015/03/150324132230.htm (accessed May 23, 2017).

RELATED STORIES